Skip to main
EW
EW logo

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 39 analyst ratings
Buy
Strong Buy 23%
Buy 38%
Hold 36%
Sell 3%
Strong Sell 0%

Bulls say

Edwards Lifesciences anticipates robust revenue growth, projecting total sales of $5.83 billion by 2025, representing a 9.2% year-over-year increase, bolstered by a $4.27 billion revenue estimate from its transcatheter aortic valve replacement (TAVR) segment, which is expected to grow at 6.4% year-over-year. The company has demonstrated strong performance in its transcatheter mitral and tricuspid technologies, with exceptional TMTT growth of 85% year-over-year, reflecting significant market demand and positioning. Additionally, Edwards Lifesciences' global sales strength, with approximately 60% of total sales derived from international markets, further underscores its expansive growth potential in the evolving cardiovascular device landscape.

Bears say

Edwards Lifesciences anticipates that both total company and transcatheter aortic valve replacement (TAVR) growth rates for Q1 2025 will fall below the lower bounds of their previously established full-year guidance ranges, largely due to the impact of one less selling day. Additionally, potential revenue growth headwinds are identified, including macroeconomic factors, slower market uptake for TAVR, challenges in penetrating the transcatheter mitral valve replacement (TMVR) market, and increasing competition. Furthermore, the impact of foreign exchange fluctuations is projected to present a significant headwind, estimated at approximately $130 million, which could negatively affect overall sales performance.

Edwards Lifesciences (EW) has been analyzed by 39 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 38% recommend Buy, 36% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 39 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Aug 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.